Matinas BioPharma (NASDAQ: MTNB)

MTNB-300
Matinas BioPharma is a development stage biopharmaceutical company, founded in 2011, with a focus on identifying and developing novel pharmaceutical products for the treatment of abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular and metabolic disease. Matinas is building on the extensive and proprietary research and development capabilities of its founding management team. The Matinas BioPharma team brings a cumulative multi-decade omega-3 pharmaceutical development and commercialization experience to the Company, providing a unique perspective and capability for creating the next generation of omega-3-fatty-acid-based pharmaceutical products.

AT A GLANCE | COMPANY NEWS | COMPANY WEBSITE SEC FILINGS STOCK QUOTE


Comments are closed.